Did you know: The 340B programs we manage are built on performance, not promise. Our team supports physicians, nurses and hospital administrators in building a bright future for HTCs/BDCs and…
Read More
Brand-Name Amicar® No Longer Available Updated March 17, 2023 Akorn Pharmaceuticals, manufacturer of Amicar® (aminocaproic acid) in both liquid and tablet form, filed for bankruptcy and has closed their doors….
Did you know: The 340B programs we manage are built on performance, not promise. Our team supports physicians, nurses and hospital administrators in building a bright future for HTCs/BDCs and…
Extending the Reach of Your340B Outpatient Factor Program March 2022 – RCE’s Specialty Pharmacy is now in network with the following national and local PBMs: What does this mean for…
Alert! Many Insurance Plans Change on 01/01/22 Throughout the month of January, please remember to verify every patient’s insurance coverage and request a copy of their insurance card(s). If they…
Specialty Pharmacy Excellence Confirmed! Irvine, CA (September 7, 2021) — Red Chip Enterprises (RCE) is pleased to announce their recertification for the prestigious URAC accreditation for Specialty Pharmacy. By earning…
Specialty Pharmacy Excellence Acknowledged Irvine, California, Red Chip of Nevada proudly announces it has achieved Specialty Pharmacy accreditation through the Accreditation Commission for Health Care (ACHC). Accreditation is a process…
April 2021 – The recently enacted American Rescue Plan Act (3/11/21), provides for a 100% federally-financed subsidy of COBRA insurance premiums for certain eligible individuals from April 1, 2021 –…
April 2021 – We’re pleased to announce as of April 1, 2021 Red Chip Pharmacy was added to Alexion Pharmaceutical’s Specialty Pharmacy Network. Similar to the way pharmaceuticals are currently…
January 21, 2021 – Fantastic news as we start the New Year! Medicare will now cover factor for patients residing in a Skilled Nursing Facility (SNF)! Traditionally this has been…
January 2020 — The 2020 340B HRSA Grantee Recertification period for Comprehensive Hemophilia Treatment Centers is January 27 – February 24, 2020. According to a recent notification from HRSA, there are some…
November 2019 — On November 1, CMS issued their final rule for the upcoming calendar Year (CY2020) which includes finalizing the proposal to continue paying an adjusted amount (ASP – 22.5%)…
Pub May 2019 Red Chip is proud to sponsor the 2019 HTRS/NASTH Scientific Symposium. If you are planning to attend the meeting, please stop by to say hello at Booth #T19. 26 HTCs have…
Partnering for Distribution Allows Greater Access Irvine, CA – Red Chip Enterprises announces they have partnered with Emmaus Life Sciences, Inc. via a limited distribution network to allow Red Chip…
January 2019 — It’s a new year…so that means reimbursement challenges aplenty for all of us! In addition to narrowed formularies and increased tiers for high-priced medications, many patients will also…
This Designation Demonstrates the Highest Level of Commitment to Quality Healthcare Irvine, CA (August 27, 2018) — Red Chip Enterprises (RCE) is pleased to announce they have received the prestigious…
August 2018 — Express Scripts, the largest PBM in the U.S., recently published a preliminary draft of their 2019 Preferred Formulary Exclusion List and there are a few notable changes…
January 2018 — Red Chip Enterprises (RCE) is pleased to announce its support of the upcoming HTRS/NASTH Research Colloquium entitled “Developing a Sustainable Research Career in Hemostasis and Thrombosis” to…
January 2018— On December 21, 2017, Rep. Larry Bucshon (R-IN) and Rep. Scott Peters (D-CA) introduced the 340B Pause Act, (H.R. 4710) in the U.S. House of Representatives. The bill…
February 2017— In response to an Executive Order titled “Executive Order Minimizing the Economic Burden of the Patient Protection and Affordable Care Act Pending Repeal”, HRSA has withdrawn its Mega-Guidance from White House review. White...
Read More
Beginning Jan. 1, 2017, United Healthcare (UHC) placed commonly prescribed AHF in higher tiered categories on their prescription formulary. Individual plans vary, but some factor products may only be available at...
Read More
Many new long-acting factor products are now available for the treatment of bleeding disorders. These products offer flexibility and enhanced lifestyle for patients who wish to dose less frequently. However,...
Read More
The recent recall of Helixate and Kogenate could have caused pandemonium as concern from patients and their families escalated. Instead, Red Chip was on the job doing what we do...
Read More
2016 is off to a fast start and that means a large portion of your patients have probably had changes of some kind to their insurance plans. This could include changes made during...
Read More
More Resources For You Compliance and 340B regulations are a hot topic right now. That’s why Red Chip Enterprises (RCE) is pleased to announce we recently renewed our retainer with Powers, Pyles, Sutter...
Read More
September 1, 2015 — The long awaited “Mega-Reg” is here and it could impact your 340B Program in significant ways. This Omnibus Guidance attempts to clarify current 340B Program requirements...
Read More
Important Manufacturer News! Red Chip Pharmacy’s Manager learned this week that liquid Amicar, the medication often used to treat minor mouth and nose bleeds in patients with clotting disorders, is on very...
Read More
June 4, 2015 — Bayer contacted our Purchasing department this week to communicate that they are experiencing a shortage of specific assays of Kogenate. Bayer reports having very limited stock of...
Read More
Red Chip Enterprises Launches In-House Dispensing Pharmacy in Support of Hemophilia Treatment Centers Utilizing Red Chip's Suite of 340B Management Services Irvine, California, March 16, 2015 — Red Chip Enterprises (RCE)...
Read More
Many manufacturers have introduced new programs that offer financial assistance for patient copays, deductibles and out-of-pocket expenses. This is great news for HTCs with 340B Factor Programs when patients are unable to...
Read More